UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2026

Commission File Number: 001-42810

YD Bio Limited

12F., No. 3, Xingnan St.,

Nangang Dist.,

Taipei City 115001, Taiwan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

~~Changes~~Appointment ~~in Board~~ of Certain Directors

On January 16, 2026, YDthe ~~Bio~~Board ~~Limited~~of Directors (the “~~Company~~Board”) orof ~~the “Registrant”) announced that~~ YD ~~Biopharma~~Bio ~~Holding~~ Limited ~~and~~(the EG“Company”) ~~Biomed~~approved ~~Limited,~~the ~~two~~appointment ~~stockholders~~ of ~~the~~Dr. ~~Company~~Chang ~~whose combined~~as ~~holdings~~Chairman ~~constitute a majority~~ of the ~~Company’s~~Compensation ~~voting~~Committee ~~rights,~~and ~~delivered~~as a ~~shareholders’ written consent (the “Written~~ ~~Consent”)~~member toof the Company’s ~~registered~~Audit ~~office~~Committee ~~pursuant~~and toNominating ~~the Company’s governing documents~~ and ~~the~~Corporate ~~applicable~~Governance ~~laws~~Committee, ofeffective ~~the~~immediately. ~~Cayman~~Additionally, ~~Islands.~~on ~~According~~January to16, ~~the Written Consent~~2026, ~~four members of~~ the ~~Company’s~~ Board ofapproved ~~Directors (~~the ~~“Board”),~~appointment ~~Joe~~of ~~Douglas~~Dr. ~~Ramsey, Albert~~Lu ~~Scott McLelland, Michaela Ann Griggs and Janet Hall, were removed~~ as ~~directors~~Chairman ~~effective~~of ~~December~~the ~~30,~~Nominating ~~2025,~~ and ~~two~~Corporate ~~new~~Governance ~~directors,~~Committee ~~Dr. Kochi Chang~~ and ~~Dr.~~as ~~Shao-Da~~a Lumember ~~were~~of ~~elected~~the toCompany’s ~~the~~Audit ~~Board~~Committee ~~effective~~and ~~December~~Compensation 30Committee, ~~2025~~effective immediately.

Dr. ~~Kochi~~ Chang ~~has~~and ~~served~~Dr. asLu ahave ~~Member~~no ofdirect ~~the~~or ~~Advisory Committee~~indirect atmaterial ~~the~~interest ~~Intelligent~~in any ~~Computing~~transaction ~~Research~~required ~~Laboratory,~~to ~~California~~be ~~State~~disclosed ~~University~~pursuant ofto ~~Fullerton,~~Item 404(a) ~~nonprofit~~of ~~research~~Regulation ~~institution since May 2022. Previously~~S-K, heand ~~was~~have ~~the~~no ~~Director~~arrangement ofor ~~the~~understanding ~~Prosthetics~~with ~~Division at Dentsply International, a for-profit manufacturer of medical~~any ~~devices~~other ~~from~~person ~~June~~required ~~2006~~ to ~~August~~be ~~2013.~~disclosed Hepursuant ~~co-founded~~to ~~and~~Item ~~has~~401(a) ~~served as the Chairman and CEO~~ of ~~Prident~~Regulation ~~International Inc~~S-K. ~~in California since January 2003.~~ Dr. Chang ~~earned~~and ~~his~~Dr. ~~Bachelor~~Lu ofhave ~~Dentistry~~no ~~degree~~family ~~from~~relationships ~~the~~required to ~~School~~be ofdisclosed ~~Dentistry~~pursuant atto ~~Taipei~~Item ~~Medical~~401(d) ~~University~~of inRegulation ~~Taiwan~~S-K.

~~Dr.~~Additionally, ~~Shao-Da~~on LuJanuary ~~has~~20, ~~served~~2026, as the ~~Director~~Company atnotified LüNasdaq ~~Shao-Da~~that ~~Holistic~~the ~~Health~~Company ~~Clinic since October 1992. He~~ has ~~served~~regained ascompliance with the ~~Deputy~~requirements ~~Secretary-General~~for at the ~~National~~Audit ~~Federation~~Committee ofpursuant ~~Medical Doctors’~~to ~~Associations,~~Nasdaq ~~Republic~~Listing ofRule ~~China since Aug 2017. From September 1983 to August 1987~~5605, heand ~~worked as a specialist in internal~~that ~~medicine~~the atCompany ~~Linkou~~is ~~Chang~~no ~~Gung~~longer ~~Memorial~~subject ~~Hospital. From September1981~~ to ~~August 1982, he was a pediatrician at~~ the ~~Taipei~~cure ~~Women~~period ~~and~~under ~~Children’s Hospital.~~Nasdaq HeListing ~~also~~Rule ~~holds management and directorship positions at several medical professional associations~~5605(c)(4)(B). ~~Dr. Lu earned his M.D. from~~ ~~China Medical University, College of Medicine.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

January 1621, 2026

	YD BIO LIMITED

	By:	/s/ Edmund Hen
	Name:	Edmund Hen
	Title:	Chief Financial Officer

Filing Compare · YD Bio Ltd